Nothing satisfies me more than seeing technology and innovation applied to solve societal problems and make breakthroughs that improve how people live and work. Advancing the medical field and finding new cures to diseases is near the top of the list.
Accenture and quantum software firm 1QBit collaborated with Biogen to develop a first-of-its-kind quantum-enabled molecular comparison application that could significantly improve advanced molecular design to speed up drug discovery for complex neurological conditions such as multiple sclerosis, Alzheimer’s, Parkinson’s and Lou Gehrig’s Disease.
Together we conducted an experiment to apply quantum computing to accelerate the drug discovery R&D process and support new therapies for patients with complex neurological conditions like multiple sclerosis, Alzheimer’s, Parkinson’s and Lou Gehrig’s disease. Read the full press release.
Quantum computing—a compute paradigm that can find the answer to complex business problems millions of times faster than classical computing by leveraging the properties of quantum physics—has been on Accenture’s radar for the last few years.
The quantum computing field represents an entirely new generation of computing power and speed, and I believe it will fundamentally change how innovation is accomplished across enterprises in every industry. Get ready to be amazed—again and again.
Like many emerging technologies, quantum computing advancements are moving quickly—and I predict that the first enterprise applications leveraging adiabatic quantum computers, as well as the subsequent adoption in business, to come in the next two to five years. The rapid uptick in quantum computing market activity confirms this trend.
At Accenture, we’re helping clients get ready for this new echelon of quantum computing now. This is just one of many quantum R&D experiments we’re running in Accenture Labs. You’ll be hearing more about Accenture’s point of view and work in quantum computing in the coming weeks and months.